Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.

The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...

January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.

The FDA has cleared the research organization's investigational new drug application, allowing it to start clinical tests of the experimental treatment DT2-SCT.